Skip to main content
Year archive

BioInvent International — 2020 filings

All 55 regulatory filings released by BioInvent International (BINV) in 2020, sourced directly from the official regulator.

55 Filings
2020 Period
2020 filings (55)
Filing Released Lang
Ändring av antalet aktier och röster i BioInvent International AB
Declaration of Voting Results & Voting Rights Announcements
2020-12-30 Swedish
BioInvent erhåller betalning på 3 miljoner USD avseende val av antikroppar inom ramen för samarbetet med Pfizer Inc.
Capital/Financing Update
2020-12-23 Swedish
Avstämningsdag för sammanläggning av aktier i BioInvent International AB fastställd
Declaration of Voting Results & Voting Rights Announcements
2020-12-07 Swedish
Record date for reverse share split in BioInvent International determined
Share Issue/Capital Change
2020-12-07 English
Resolutions at the Extraordinary General Meeting in BioInvent on November 27, 2020
AGM Information
2020-11-27 English
Beslut på BioInvents extra bolagsstämma den 27 november 2020
AGM Information
2020-11-27 Swedish
Earnings Release 2020
Earnings Release 9M 2020
2020-10-29 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q3 2020
2020-10-29 English
Notice to Extraordinary General Meeting in BioInvent International AB
AGM Information
2020-10-27 English
Kallelse till extra bolagsstämma i BioInvent International AB
AGM Information
2020-10-27 Swedish
BioInvent licensierar anti-Fc?RllB-antikroppen BI-1206 till CASI Pharmaceuticals för den kinesiska regionen
Regulatory Filings
2020-10-27 Swedish
BioInvent erhåller milstolpsbetalning på 2 miljoner euro från Daiichi Sankyo
Capital/Financing Update
2020-10-22 Swedish
Ändring av antalet aktier och röster i BioInvent International AB
Declaration of Voting Results & Voting Rights Announcements
2020-08-31 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q2 2020
2020-08-27 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report H1 2020
2020-08-27 English
BioInvent’s repair rights issue of approximately SEK 139 million was heavily oversubscribed
Capital/Financing Update
2020-08-05 English
BioInvents kompensationsemission om cirka 139 MSEK var kraftigt övertecknad
Capital/Financing Update
2020-08-05 Swedish
Major Shareholding Notification 2020
Major Shareholding Notification
2020-08-04 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-08-03 English
Ändring av antalet aktier och röster i BioInvent International AB
Share Issue/Capital Change
2020-07-31 Swedish
Change in the number of shares and votes in BioInvent International AB
Declaration of Voting Results & Voting Rights Announcements
2020-07-31 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-07-23 English
BioInvent publishes prospectus relating to the rights issue
Capital/Financing Update
2020-07-17 English
BioInvent offentliggör prospekt avseende företrädesemissionen
Report Publication Announcement
2020-07-17 Swedish
Major Shareholding Notification 2020
Major Shareholding Notification
2020-07-10 English
BioInvent’s Board of Directors resolve on a repair rights issue of a maximum of approx. SEK 139 million, following the successfully completed directed share issue of approx. SEK 487 million
Capital/Financing Update
2020-07-09 English
BioInvents styrelse har beslutat om en kompensationsemission om upp till cirka 139 MSEK, efter den framgångsrikt genomförda riktade emissionen om cirka 487 MSEK
Share Issue/Capital Change
2020-07-09 Swedish
Major Shareholding Notification 2020
Major Shareholding Notification
2020-07-09 Swedish
Major Shareholding Notification 2020
Major Shareholding Notification
2020-07-08 English
BioInvent publishes prospectus regarding admission to trading of newly issued shares on Nasdaq Stockholm
Share Issue/Capital Change
2020-07-08 English
BioInvent offentliggör prospekt avseende upptagande till handel av nyemitterade aktier på Nasdaq Stockholm
Capital/Financing Update
2020-07-08 Swedish
Major Shareholding Notification 2020
Major Shareholding Notification
2020-07-06 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-07-06 Swedish
Beslut på BioInvents extra bolagsstämma den 3 juli 2020
Share Issue/Capital Change
2020-07-03 Swedish
Change in the number of shares and votes in BioInvent International AB
Declaration of Voting Results & Voting Rights Announcements
2020-06-30 English
Ändring av antalet aktier och röster i BioInvent International AB
Share Issue/Capital Change
2020-06-30 Swedish
Förslag till ny styrelseledamot att utses vid den extra bolagsstämman den 3 juli 2020
Board/Management Information
2020-06-18 Swedish
Proposal for a new Board member to be elected at the Extraordinary General Meeting on July 3, 2020
Board/Management Information
2020-06-18 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-06-10 English
Notice to Extraordinary General Meeting in BioInvent International AB
AGM Information
2020-06-09 English
Kallelse till extra bolagsstämma i BioInvent International AB
AGM Information
2020-06-09 Swedish
BioInvent genomför framgångsrikt en riktad emission av aktier om cirka 487 MSEK (cirka 47 MEUR)
Capital/Financing Update
2020-06-09 Swedish
BioInvent successfully completes a directed share issue of approximately SEK 487 million (approximately EUR 47 million)
Capital/Financing Update
2020-06-09 English
Beslut på BioInvents årsstämma 2020
AGM Information
2020-05-28 Swedish
Resolutions at BioInvent’s Annual General Meeting 2020
AGM Information
2020-05-28 English
Notice to Annual General Meeting in BioInvent International AB
AGM Information
2020-04-28 English
Kallelse till årsstämma i BioInvent International AB
AGM Information
2020-04-28 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q1 2020
2020-04-28 Swedish
Earnings Release 2020
Earnings Release Q1 2020
2020-04-28 English
BioInvent reports promising progress in Phase I/lla trial of lead program BI-1206 in combination with rituximab
Earnings Release FY 2020
2020-04-14 English
BioInvent rapporterar lovande framsteg i fas I/IIa-studien med det ledande programmet BI-1206 i kombination med rituximab
Regulatory Filings
2020-04-14 Swedish
Annual Report 2019
Annual Report FY 2019
2020-04-08 Swedish
Annual Report 2019
Annual Report FY 2019
2020-04-08 English
Earnings Release 2019
Earnings Release Q4 2019
2020-02-27 Swedish
Earnings Release 2019
Earnings Release Q4 2019
2020-02-27 English